6.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRVI Giù?
Forum
Previsione
Precedente Chiudi:
$6.75
Aprire:
$6.76
Volume 24 ore:
1.09M
Relative Volume:
0.38
Capitalizzazione di mercato:
$969.12M
Reddito:
$204.73M
Utile/perdita netta:
$-184.29M
Rapporto P/E:
-9.0922
EPS:
-0.7226
Flusso di cassa netto:
$-51.87M
1 W Prestazione:
-2.81%
1M Prestazione:
+5.29%
6M Prestazione:
+95.54%
1 anno Prestazione:
+180.77%
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Nome
Maravai Lifesciences Holdings Inc
Settore
Industria
Telefono
(858) 546-0004
Indirizzo
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings Inc
|
6.57 | 986.82M | 204.73M | -184.29M | -51.87M | -0.7226 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Iniziato | Guggenheim | Neutral |
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Iniziato | Craig Hallum | Buy |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-08-08 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Downgrade | Goldman | Buy → Neutral |
| 2023-01-05 | Downgrade | UBS | Buy → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-11-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2020-12-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Iniziato | Credit Suisse | Outperform |
| 2020-12-15 | Iniziato | Goldman | Buy |
| 2020-12-15 | Iniziato | Jefferies | Buy |
| 2020-12-15 | Iniziato | Robert W. Baird | Outperform |
| 2020-12-15 | Iniziato | Stifel | Buy |
| 2020-12-15 | Iniziato | William Blair | Outperform |
| 2020-12-14 | Iniziato | UBS | Buy |
Mostra tutto
Maravai Lifesciences Holdings Inc Borsa (MRVI) Ultime notizie
Maravai LifeSciences Holdings Inc - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Cash Flow - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.760|Chg%:-0.290 - TradingKey
TradingKey - TradingKey
MRVI|Maravai LifeSciences Holdings Inc|Price:6.690|Chg%:-0.070 - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News - Moomoo
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences - The National Law Review
Maravai LifeSciences to announce Q2 results on August 6 - scanx.trade
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026 - Business Wire
Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A – FWB:MAR - TradingView
MRVI Secures New Patent for RNA Synthesis Technology - GuruFocus
TriLink receives China patent for CleanCap mRNA technology - Investing.com
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology - Yahoo Finance
TriLink BioTechnologies Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap Capping Technology - Finviz
Maravai Lifesciences Holdings stock hits 52-week high at 7.1 USD - Investing.com Nigeria
Form 4 Maravai Lifesciences Holdings Inc For: 10 July By Investing.com - Investing.com Nigeria
Maravai Lifesciences (MRVI) CEO reports 29,250-share tax withholding event - Stock Titan
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 - AOL.com
Maravai Q1 2026 slides: 41% revenue surge drives profitability return - Investing.com
Price to book forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
Millennium Management LLC Reduces Stake in Maravai LifeSciences Holdings Inc - GuruFocus
MRVIMaravai LifeSciences Holdings Inc Volatility & Greeks - Finviz
Maravai LifeSciences stock. Identity holds, but no live catalyst is surfaced. - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeScience - The National Law Review
Form 4 Maravai Lifesciences Holdings Inc For: 1 July By Investing.com - Investing.com Canada
Maravai (MRVI) CFO has 65,584 shares withheld for RSU tax - Stock Titan
Maravai LifeSciences (MRVI) Slips 3.83% as Stock Nears Critical Support AreaWatchlist Stock Ideas - DonanımHaber
Millennium Management reports >5% stake then falls below 5% in MRVI (MRVI) - Stock Titan
ETFs Investing in Maravai Lifesciences Holdings, Inc. Class A Stocks - TradingView
Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A – SWB:MAR - TradingView
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronste - The National Law Review
Maravai LifeSciences (MRVI) Investor presentation Summary - Quartr
Maravai Lifesciences Hits New 52-Week High at $5.42 - MarketsMojo
Maravai Lifesciences Hits New 52-Week High of $5.29, Marking Significant Milestone - MarketsMojo
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Maravai Lifesciences Hits New 52-Week High of $6.21 - MarketsMojo
Price to sales forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
MAR Forecast — Price Target — Prediction for 2027 - TradingView
Maravai LifeSciences Holdings Inc (MRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBIT forward of Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI - TradingView
Maravai Lifesciences Holdings, Inc. Class A Actuals & Estimates (NASDAQ:MRVI) - TradingView
MRVI Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Maravai LifeSciences Holdings For: 23 June By Investing.com - Investing.com Australia
Millennium (MRVI) reports 7.32M shared stake, 4.96% as of Jun 16, 2026 - Stock Titan
Maravai Lifesciences Holdings Inc Azioni (MRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maravai Lifesciences Holdings Inc Azioni (MRVI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):